VJVilija G. Jokubaitis

Vilija G. Jokubaitis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vilija G. Jokubaitis has a total of 837 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From Exposure to Disease

    by Vilija G. Jokubaitis, Raffaele Palladino

  • Cognitive trajectories across the menopausal transition in women with multiple sclerosis: an exploratory longitudinal cohort study

    by Francesca Bridge, Paul G. Sanfilippo, David Darby, Helmut Butzkueven, Vilija G. Jokubaitis, Daniel Merlo, Anneke van der Walt

  • Open Access

    How patients with neuromyelitis optica spectrum disease accumulate disability

    by Sifat Sharmin, Izanne Roos, Pakeeran Siriratnam, Serkan Ozakbas, Dana Horáková, Eva Kubala Havrdova, Petra Nytrová, Recai Turkoglu, Francesco Patti, Bassem Yamout, et al.

    Background: It is believed that patients with neuromyelitis optica spectrum disease acquire disability exclusively through relapses. However, the possibility of disability accumulation in the absence of relapses has also been suggested. We quantified irreversible disability accumulation in the presence and absence of relapses in neuromyelitis optica spectrum disease. Methods: We identified patients with neuromyelitis optica spectrum disease in the MSBase registry. Disability-worsening events were required to be sustained until the end of follow-up. Worsening in the absence of relapses was validated through primary record review. Results: Over 884 patient-years of follow-up, we identified 32 disability-worsening events in 31 patients. Notably, six events (18.7%) in five patients (1.9%) occurred in the absence of relapses. A positive association was identified between relapse trajectory and the hazard of disability worsening (hazard ratio (95% credible interval): 2.36 (1.61, 3.64)), and an inverse relationship with disability worsening occurring in the absence of relapses (0.41 (0.11, 1.47)). Conclusion: Irreversible disability worsening was rare in this proactively treated cohort of neuromyelitis optica spectrum disease patients (3.6 events per 100 patient-years). However, almost 19% of worsening occurred in the absence of relapses, reassuringly in only 2% of patients. Our findings support relapses as the principal driver of disability in neuromyelitis optica spectrum disease while also providing evidence of relapse-independent disability worsening beyond identifiable comorbidities.

  • Open Access

    Lymphocyte count polygenicity underlies dimethyl fumarate–associated lymphopenia in multiple sclerosis

    by Kaarina Kowalec, Ali Manouchehrinia, Elaine Kingwell, Robert Carruthers, Ruth Ann Marrie, Charity Evans, Dalia Rotstein, Annie J Kuan, Wenzhuo Luo, Daniel Luo, et al.

    Purpose: One in 20 people using dimethyl fumarate (DMF), a commonly used disease-modifying therapy for multiple sclerosis (MS), develops severe lymphopenia. We aimed to identify genetic variation associated with DMF-related lymphopenia. Methods: Using a case–control design, we included cases that had either grade 2 (absolute lymphocyte count 9 /L) or 3 (9 /L) lymphopenia during DMF. Controls had normal lymphocyte counts and ⩾1 year of DMF exposure. We generated a polygenic score for lymphocyte counts and evaluated its ability to predict DMF-associated lymphopenia in two cohorts, with adjustment for covariates. We also conducted a genome-wide association study (GWAS) and gene-based analyses. Findings: The discovery cohort comprised 238 PwMS of European genetic ancestry from Canada/Australia ( n = 72 grade 2 cases, 34 grade 3 cases), and the replication cohort comprised 156 PwMS from Sweden ( n = 34 grade 2, 14 grade 3). A higher polygenic score for lymphocyte counts predicted reduced risk of grade 2 lymphopenia (hazard ratio = 0.43, 95% confidence interval: 0.25–0.73). The GWAS identified one locus associated with the minimum lymphocyte count during DMF (rs17087205, beta = −0.63, SE = 0.11, p = 3.89e–8) but did not replicate (beta = −0.04, p = 0.47). Conclusion: Common polygenic variation of lymphocyte counts was significantly associated with moderate lymphopenia during DMF treatment.

  • Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data

    by Chao Zhu, Sandra Vukusic, Tomas Kalincik, Guillaume Mathey, Allan G Kermode, Elisabeth Maillart, Jeannette Lechner-Scott, Emanuelle Le Page, Izanne Roos, Jonathan Ciron, et al.

    Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. Methods We conducted an observational cohort study emulating a target trial using data from the MSBase and Observatoire Français de la Sclérose en Plaques registries (January 2021 to December 2024). Adults with RRMS initiating ofatumumab or ocrelizumab were included. Patients were matched 1:1 using propensity scores. Primary outcomes were annualised relapse rate (ARR) and time to first relapse. Secondary outcomes included time to confirmed disability progression (CDP), progression independent of relapse activity (PIRA), confirmed disability improvement (CDI), MRI activity and treatment discontinuation. Negative binomial and Cox regression models were applied. Results A total of 5288 patients were matched with a median follow-up of 1.2 years for ofatumumab and 1.4 years for ocrelizumab. ARR was 0.07 (95% CI 0.05 to 0.08) with ofatumumab and 0.04 (0.03 to 0.05) with ocrelizumab, corresponding to an ARR ratio of 1.75 (1.43 to 2.13). Ofatumumab was associated with a lower risk of CDP (HR 0.66; 0.49 to 0.87) and PIRA (0.53; 0.39 to 0.73), but a lower probability of CDI (0.76; 0.60 to 0.96). No significant differences were observed in MRI activity or treatment discontinuation. Conclusions Both therapies were highly effective in a large cohort of patients with RRMS, with very low relapse or CDP rates. Ofatumumab was associated with slightly greater disability control, while ocrelizumab more effectively suppressed relapses. These differences were modest, and their clinical relevance requires further evidence and should be interpreted with caution.

  • Open Access

    Genetic Risk in Multiple Sclerosis: Susceptibility, Modifiers and Unresolved Questions

    by Jingni He, Nicholas B. Blackburn, Vilija G. Jokubaitis


  • Open Access

    Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study

    by Cassie Nesbitt, Paul Sanfilippo, Chao Zhu, Serkan Ozakbas, Alexandre Prat, Marc Girard, Pierre Duquette, Tomas Kalincik, Izanne Roos, Katherine Buzzard, et al.

    Background and objective: As more people with multiple sclerosis (MS) survive cancer, questions about MS management after cancer are increasingly relevant. This study aimed to describe post-cancer treatment patterns and MS outcomes in people with recorded chemotherapy exposure. Methods: Using MSBase, we identified people with MS with cancer and chemotherapy exposure. Time to first relapse and 6-month confirmed disability progression (CDP) were analysed using Cox models with disease-modifying therapy (DMT) as a time-varying covariate. Outcomes were contextualised using 1:2 propensity-matched MS controls without cancer or chemotherapy. Results: In total, 363 individuals were followed for 2.8 years (median) after cancer. Older age at cancer was associated with lower relapse hazard (hazard ratio (HR) = 0.96 per year, p = 0.008), while DMT category was not. The DMT category was not associated with CDP. In matched analysis (256 vs. 505), relapse hazard was lower during the first year after cancer (HR = 0.30, p = 0.015) with no difference thereafter; CDP risk was similar (HR = 1.13, p = 0.60). Conclusion: Post-cancer DMT category was not associated with relapse or CDP. Lower first-year relapse hazard, together with lower relapse hazard at older age, may provide cautious reassurance regarding early post-cancer inflammatory activity in similar clinical contexts, although the drivers of the first-year signal remain uncertain.

  • Open Access

    Association between pregnancy timing and disability outcomes in women with mild relapse-onset multiple sclerosis

    by Jessica Shipley, Chao Zhu, Paul G Sanfilippo, Olga Skibina, Tomas Kalincik, Raed Alroughani, Bruce V Taylor, Richard Macdonell, Vicki E Maltby, Jeannette Lechner-Scott, et al.

    Background: Pregnancy does not adversely affect disability outcomes in women with multiple sclerosis (MS). However, it remains uncertain whether pregnancy is associated with slower disability accumulation, and whether this association differs according to the timing of pregnancy during the disease course. Methods: This observational cohort study used prospectively ascertained data in the international MSBase Registry (1991–2022), supplemented with retrospective surveys detailing participants’ complete pregnancy histories. The study included women with mild relapse-onset MS, defined as an Expanded Disability Status Scale (EDSS) score of 2.5 or below. A flexible parametric survival model was used to assess the time-varying effect of live-birth pregnancy on reaching sustained EDSS 3. Results: We included 2079 women, of whom 571 had a live-birth pregnancy after baseline. Live-birth pregnancies occurring within the first 4.42 years of follow-up were associated with longer time to sustained EDSS 3. At 10 years, live birth was associated with an absolute cumulative difference of 0.51 years in time to this disability milestone (95% confidence interval (CI): 0.23, 0.79). Among women with live births, postpartum relapses were associated with shorter time to sustained EDSS 3 (hazard ratio (HR): 1.61; 95% CI: 1.02, 2.55). Conclusion: Live-birth pregnancy occurring earlier in follow-up was associated with a longer time to disability accrual.


  • Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD

    by Pakeeran Siriratnam, Cordelia Dunai, Nkongho Egbe Franklyn, Samantha Linaker, Robb Wesselingh, Anu Jacob, Edward Joseph Jackson, Anneke van der Walt, Vilija Jokubaitis, Helmut Butzkueven, et al.

    Background and objectives: Disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disease (AQP4-IgG NMOSD) is considered relapse-driven although subclinical injury has been suggested by neuroimaging and visual pathway assessments. We investigated longitudinal changes in serum glial fibrillar acidic protein (sGFAP) and neurofilament light chain (sNfL) during relapse-free periods. Methods: We conducted a retrospective longitudinal study (2008–2025) at a UK national referral centre for NMOSD. Patients with ≥3 serum samples collected over ≥3 years were included; samples within 3 months of relapses were excluded. Longitudinal changes in sGFAP and sNfL were assessed using linear mixed-effects models with random intercepts and generalised estimating equations, adjusting for age, sex and time. Results: 40 patients (87.5% females; 162 samples; median onset age 40.1 years) and 28 matched controls were included. Over the course of four measurements and a median sampling over 9 years, stability was observed in sGFAP levels (99.2 pg/mL at 0–2.5 years (95% CI 84.2 to 117.0) to 90.3 pg/mL at 7.5–10 years (95% CI 74.7 to 109.0), p=0.65) and sNfL levels (12.0 pg/mL at 0–2.5 years (95% CI 10.8 to 13.3) to 10.4 pg/mL (9.1 to 11.8) at 7.5–10 years, p=0.12) after adjustment for covariates. Discussion: In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.

  • Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

    by Pakeeran Siriratnam, Vilija G. Jokubaitis, Anneke Van Der Walt, Paul G. Sanfilippo, Chao Zhu, Masoud Etemadifar, Ayse Altintas, Abdullah Al-Asmi, Guy Laureys, Jose E. Meca-Lallana, et al.

    Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD. We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models. Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability. Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment.